会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Content usage-right management system and management method
    • 内容使用权管理制度和管理办法
    • US07496756B2
    • 2009-02-24
    • US10415852
    • 2002-08-15
    • Makoto OkaYoshihito IshibashiHiroshi AbeNoboru ShimadaMasahiko EnariKenji Yoshino
    • Makoto OkaYoshihito IshibashiHiroshi AbeNoboru ShimadaMasahiko EnariKenji Yoshino
    • H04L9/00
    • G06Q30/06G06F21/10
    • A system in which content usage conditions can be upgraded without the need for a service provider to control content-usage rights of a user. In the system in which encrypted content is distributed and is allowed to be utilized only by authorized users, the service provider receives a content usage-right certificate from the user, and on the condition that it is determined that data is not tampered with by verifying a digital signature of an issuing entity of the content usage-right certificate, the service provider obtains user information and content purchase information of the user from the content usage-right certificate, and performs upgrade processing by, for example, changing the usage conditions. It is thus possible to change the content usage conditions without the need for the service provider to possess usage control data.
    • 可以在不需要服务提供者来控制用户的内容使用权限的情况下升级内容使用条件的系统。 在加密内容被分发且仅被授权用户被允许使用的系统中,服务提供商从用户接收内容使用权证书,并且在确定数据未被篡改的情况下通过验证 内容使用权证书的发行实体的数字签名,服务提供者从内容使用权证书中获取用户的用户信息和内容购买信息,并且通过例如改变使用条件来执行升级处理。 因此,可以在不需要服务提供者拥有使用控制数据的情况下改变内容使用条件。
    • 8. 发明授权
    • 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivatives
    • 5-取代-3-恶二唑基-1,6-二氮杂萘-2(1H) - 酮衍生物
    • US06172079B2
    • 2001-01-09
    • US09462412
    • 2000-01-10
    • Kazunori OhnoOsamu OdaiKaoru MasumotoKiyoshi FurukawaMakoto Oka
    • Kazunori OhnoOsamu OdaiKaoru MasumotoKiyoshi FurukawaMakoto Oka
    • A61K31435
    • C07D471/04
    • A 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative of the formula (I): wherein Het is oxadiazolyl, R1 is H, lower alkyl, cyclo-lower alkyl, trifluoromethyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkoxy-lower alkyl, hydroxy-lower alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaromatic group, and R2 is H, lower alkyl, cyclo-lower alkyl, cyclo-lower alkylmethyl, lower alkenyl, cyclo-lower alkenyl, lower alkynyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaromatic group, or a pharmaceutically acceptable acid addition salt thereof, which has high selective affinity to benzodiazepine receptor and is useful particularly as a benzodiazepine inverse agonist, for example, as psychoanaleptic drug or a drug for the treatment of dysmnesia in senile dementia or Alzheimer's disease.
    • 式(I)的5-取代-3-恶二唑基-1,6-二氮杂萘-2(1H) - 酮衍生物:其中Het是恶二唑基,R 1是H,低级烷基,环低级烷基,三氟甲基,低级烯基 低级炔基,低级烷氧基,低级烷氧基 - 低级烷基,羟基 - 低级烷基,取代或未取代的芳基,或取代或未取代的杂芳基,R2是H,低级烷基,环低级烷基,环低级烷基甲基, ,环低级烯基,低级炔基,取代或未取代的芳基或取代或未取代的杂芳族基团或其药学上可接受的酸加成盐,其对苯并二氮杂受体具有高选择性亲和力,并且特别用作苯二氮卓反相激动剂,例如 作为精神无菌药物或用于治疗老年痴呆或阿尔茨海默氏症的失聪症的药物。